Intuitive Investments Group plc
Investment in Yourgene Health plc
Intuitive Investments Group plc (AIM: IIG) ("IIG" or the "Company"), a closed-end investment company focussed on the life sciences sector, announces an investment of £248,765 to acquire 1,584,920 ordinary shares of Yourgene Health plc (AIM: YGEN) ("Yourgene") at an average price of 15.70 pence per share (the "Investment").
Yourgene is an international molecular diagnostics group which develops and commercialises genetic products and services. Yourgene works in partnership with global leaders in DNA technology to advance diagnostic science.
Robert Naylor, CEO of IIG, has an investment predating IIG's investment, of 164,456 ordinary shares in Yourgene. Accordingly, Robert Naylor did not vote as a member of the investment team of IIG in approving the Investment.
The Investment in Yourgene is the Company's sixth investment following its IPO in mid-December 2020.
For further information, please contact:
| Intuitive Investments Group plc | |
| David Evans, Executive Chairman Robert Naylor, CEO | Via Walbrook PR |
|
|
|
| Strand Hanson Limited - Nominated Adviser | +44 (0) 20 7409 3494 |
| James Harris / James Dance / James Bellman
|
|
| | |
| | |
| Turner Pope Investments (TPI) Ltd - Broker | +44 (0) 20 3657 0050 |
| Andrew Thacker / Zoe Alexander |
|
|
|
|
| Walbrook PR Limited - Media & Investor Relations | +44 (0)20 7933 8780 or intuitive@walbrookpr.com |
| Sam Allen / Paul McManus | +44 (0)7748 651 727 / +44 (0) 7980 541 893 |
About Intuitive Investments Group plc (www.iigplc.com)
The Company is a newly established investing company, seeking to provide investors with exposure to a portfolio concentrating on fast growing and/or high potential Life Sciences businesses operating predominantly in the UK, continental Europe and the US, utilising the Board's experience and in particular that of the Chairman, David Evans, to seek to generate capital growth over the long term for shareholders.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
